IT Matters: The Erectile Restoration Registry
1 other identifier
observational
450
3 countries
25
Brief Summary
The objective of the It MATTERS registry is to collect Real-World Data (RWD) to monitor the safe and effective use of commercially available Boston Scientific Corporation (BSC) penile prostheses
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2021
Longer than P75 for all trials
25 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 11, 2019
CompletedFirst Posted
Study publicly available on registry
December 16, 2019
CompletedStudy Start
First participant enrolled
August 5, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2031
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2031
June 12, 2026
June 1, 2026
9.4 years
December 11, 2019
June 11, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change from baseline to six months in the Erectile Function domain ofthe International Index of Erectile Function (IIEF-EF) questionnaire for Tactra
The International Index of Erectile Function (IIEF) is a validated, widely used, multidimensional self-report instrument for the evaluation of erectile function. It consists of 15 items that assess sexual function in five domains: erectile function (Q1, 2, 3, 4, 5,15), orgasmic function (Q9,10), sexual desire (Q11,12), intercourse satisfaction (Q 6,7,8) and overall satisfaction (Q 13,14). A score of 0-5 is awarded to each of the 15 questions. The IIEF-15 total score is the sum of the ordinal responses to the 5 domains. The erectile function (EF) domain is the most sensitive domain of the IIEF. IIEF-EF score ranges from 1 to 30 and is derived by scoring 0 (poorest function) to 5 (best function) on each of six questions function (Q1, 2, 3, 4, 5, 15). There are five categories of erectile function based on EF domain score: severe (1-10), moderate (11-16), mild to moderate (17-21), mild (22-25) and no ED (26-30).
Baseline to 6 months
Secondary Outcomes (3)
Change in depressive symptoms and overall sexual function at Post-Surgery, 6 months, 12 months and annually thereafter post device implantation compared to baseline, as measured by the PHQ-9 Depression Questionnaire and the IIEF: Total Score.
Post-Surgery, 6 months, 12 months and annually thereafter through study completion, an average of 10 years
Change in quality of life at 6 months, 12 months, and 24 months post device implantation compared to baseline as measured by the WPAI:GH Questionnaire.
6 months, 12 months and 24 months
Change in erectile function at post-surgery, 12 months and annually post device implantation compared to baseline, as measured by the International Index of Erectile Function Domain (IIEF).
Post-Surgery, 12 months and annually thereafter through study completion, an average of 10 years
Other Outcomes (2)
Device satisfaction at post-surgery, 6 months, 12 months and annually thereafter measured by the Likert scale.
Post-surgery, 6 months, 12 months and annually thereafter through study completion, an average of 10 years
Assess for outcomes and adverse events on AMS Tools at Post Procedure.
Collected only at Post-Procedure
Study Arms (1)
BSC Penile Prothesis Recipients
Men for whom BSC Penile Prothesis is recommended.
Interventions
The Tactra™ Penile Prosthesis is a sterile, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in adult males who are suitable candidates for implantation procedure.
The Spectra Penile Prothesis is a sterile, non-pyrogenic, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in men who are determined to be suitable candidates for implantation surgery.
The AMS Ambicor inflatable penile prothesis intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence) in adult men who are determined to be suitable candidates for implantation surgery.
The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).
The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).
Eligibility Criteria
Adult males who meet the indications for surgical correction of erectile dysfunction will be enrolled.
You may qualify if:
- ≥ 18 years of age.
- Males who are determined to be suitable candidates and scheduled to undergo surgical implantation of a market approved BSC penile prothesis by their physician.
- Willing and able to complete the informed consent process.
- Willing and able to comply with the follow-up requirements.
You may not qualify if:
- Males who are deemed by their physician as not suitable candidates for a penile prosthesis.
- In the opinion of the investigator, it is not in best interest of the patient or the study for the patient to participate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (25)
USC Medical Center
Los Angeles, California, 90033, United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, 90095, United States
Tower Urology-Research Facility
Los Angeles, California, 99048, United States
University of Miami Hospital
Miami, Florida, 33136, United States
USF Health South Tampa Center for Advanced Healthcare
Tampa, Florida, 33606, United States
University of Chicago
Chicago, Illinois, 60637, United States
SIU School of Medicine
Springfield, Illinois, 62702, United States
Indiana University Medical Center
Indianapolis, Indiana, 46202, United States
Willis-Knighton Medical Center
Bossier City, Louisiana, 71111, United States
Washington University in St. Louis
St Louis, Missouri, 63110, United States
Duke University Medical Center
Raleigh, North Carolina, 27609, United States
W.G. Hefner VA Medical Center
Salisbury, North Carolina, 28144, United States
Wake Forest University
Winston-Salem, North Carolina, 27103, United States
Cleveland Clinic
Cleveland, Ohio, 44195, United States
Ohio State University Wexner Medical Center
Columbus, Ohio, 43212, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
Baylor College of Medicine
Houston, Texas, 77030, United States
Houston Methodist Hospital
Houston, Texas, 77030, United States
University of Utah
Salt Lake City, Utah, 84132, United States
University of Washington Medical Center
Seattle, Washington, 98195, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Peking University First Hospital
Beijing, 100034, China
Shanghai General Hospital
Shanghai, 200080, China
Shanghai Jiaotong University School of Medicine Renji Hospital
Shanghai, 200127, China
Johns Hopkins Aramco Healthcare
Dhahran, 34465, Saudi Arabia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mohit Khera, MD
Baylor College of Medicine
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 11, 2019
First Posted
December 16, 2019
Study Start
August 5, 2021
Primary Completion (Estimated)
January 1, 2031
Study Completion (Estimated)
December 1, 2031
Last Updated
June 12, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share